Menu
Search
|

Menu

Close
X

Horizon Pharma PLC HZNP.OQ (NASDAQ Stock Exchange Global Select Market)

13.88 USD
-0.01 (-0.07%)
As of Feb 20
chart
Previous Close 13.89
Open 13.85
Volume 635,490
3m Avg Volume 548,874
Today’s High 14.26
Today’s Low 13.78
52 Week High 17.68
52 Week Low 9.45
Shares Outstanding (mil) 163.35
Market Capitalization (mil) 2,211.82
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.75 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY17
782
FY16
981
FY15
757
EPS (USD)
FY17
-2.236
FY16
-1.038
FY15
0.212
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
2.15
5.77
Price to Book (MRQ)
vs sector
2.15
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
183.94
16.52
LT Debt to Equity (MRQ)
vs sector
183.12
12.22
Return on Investment (TTM)
vs sector
-13.86
14.43
Return on Equity (TTM)
vs sector
-36.88
16.13

EXECUTIVE LEADERSHIP

Timothy Walbert
Chairman of the Board, President, Chief Executive Officer, Since 2010
Salary: $950,000.00
Bonus: $1,023,150.00
Paul Hoelscher
Chief Financial Officer, Executive Vice President, Since 2014
Salary: $500,000.00
Bonus: $269,250.00
Barry Moze
Executive Vice President, Chief Administrative Officer, Since 2017
Salary: $550,000.00
Bonus: $296,175.00
Brian Beeler
Executive Vice President, General Counsel, Since 2015
Salary: --
Bonus: --
Robert Carey
Executive Vice President, Chief Business Officer, Since 2014
Salary: $500,000.00
Bonus: $269,250.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Dublin 4 1st Fl
1 Burlington Road, Connaught Hou
DUBLIN     HM 09

Phone: +3531.7722100

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), MIGERGOT (ergotamine tartrate & caffeine suppositories), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).

SPONSORED STORIES